David Feldman

Address:

2652 Cropsey Ave, Brooklyn, NY 11214

Phone:

(210)3736565

VIN:

WDCGG8HB1AF326428

Make:

MERCEDES-BENZ

Model:

GLK-CLASS

Year:

2010

US Patent:

7565322, Jul 21, 2009

Filed:

Mar 29, 2000

Appl. No.:

09/537086

Inventors:

David N. Feldman - Cambridge MA, US
Sreekant Kotay - Richboro PA, US
Robert E. Rice - Short Hills NJ, US

Assignee:

Enliven Marketing Technologies Corporation - New York NY

International Classification:

H04K 1/00
H04L 9/00

US Classification:

705 50, 705 51, 705 52, 705 53, 705 54, 705 55, 705 56, 705 57, 705 58, 705 59

Abstract:

A system and method for licensing the use of “plug-in” type software that plays audio, video, and three dimensional content which logs the network address from which content is downloaded and played by the plug-in client software, then sends this information to a billing system maintained by the plug-in software developer. This billing system can then bill the content provider that is associated with the network address based on the number of times the content is played by users of the plug-in software. The system and method can also employ a public key encryption scheme to ensure that the network address information received by the plug-in software is valid and to block the playing of content from content providers that are delinquent in their license payments.

US Patent:

8183295, May 22, 2012

Filed:

Aug 8, 2008

Appl. No.:

12/188604

Inventors:

David L Feldman - Teaneck NJ, US
Randy L Webb - Flemington NJ, US

Assignee:

Novartis Pharmaceuticals Corporation - East Hanover NJ

International Classification:

A61K 31/65
A61K 31/4418
A61K 31/4422
A61K 31/5415

US Classification:

514620, 514356, 5142232

Abstract:

The invention relates to a pharmaceutical composition comprising (i) a renin inhibitor, (ii) a calcium channel blocker (CCB), and a diuretic and to a method of using such composition for the treatment of cardiovascular disease.

US Patent:

20050124624, Jun 9, 2005

Filed:

Mar 14, 2003

Appl. No.:

10/507642

Inventors:

Richard Gilbert - Victoria, AU
Darren Kelly - Victoria, AU
David Feldman - Teaneck NJ, US

International Classification:

A61K031/549
A61K031/506
A61K031/4178
A61K031/401
A61K031/366

US Classification:

514252180, 514381000, 514423000, 514355000, 514223500, 514460000, 514548000

Abstract:

A PDGF receptor tyrosine kinase inhibitor, especially a 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof can be used in the treatment of angiotensin II-induced diseases and a combination which comprises (a) a PDGF receptor tyrosine kinase inhibitor preferably N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one compound selected from an antihypertensive, an aldosterone antagonist, an aldosterone synthase inhibitor and/or an angiotensin receptor blocker agent and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of hypertension and hypertension-induced diseases.

US Patent:

20050182042, Aug 18, 2005

Filed:

May 16, 2003

Appl. No.:

10/514683

Inventors:

David Feldman - Teaneck NJ, US
Randy Webb - Flemington NJ, US

International Classification:

A61K031/554
A61K031/549
A61K031/455

US Classification:

514211070, 514223500, 514355000

Abstract:

The invention relates to a pharmaceutical composition comprising (i) a renin inhibitor, (ii) a calcium channel blocker (CCB), and (iii) a diuretic and to a method of treatment of a condition or a disease selected from the group consisting of hypertension, heart failure such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis (including IgA nephropathy), renal fibrosis, scleroderma, glomerular sclerosis, proteinuria of renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), glaucoma and stroke, pulmonary and hepatic fibrosis, fibrotic diseases resulting from accumulation of excess extracellular matrix induced by TGF, and proliferative diseases of smooth muscle cells, including uterine fibroids comprising administering a therapeutically effective amount of said pharmaceutical composition to a mammal in need of such treatment.

US Patent:

20050209244, Sep 22, 2005

Filed:

Feb 27, 2003

Appl. No.:

10/505398

Inventors:

Margaret Prescott - Millburn NJ, US
David Feldman - Teaneck NJ, US

International Classification:

A61K031/506
A61F002/00

US Classification:

514252180, 424423000

Abstract:

The invention relates to the local administration of N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or a pharmaceutically acceptable salt or crystal form thereof, optionally in conjunction with one or more other active ingredients, and a device adapted for such local administration.

US Patent:

20070226204, Sep 27, 2007

Filed:

Dec 5, 2005

Appl. No.:

11/294678

Inventors:

David Feldman - Cambridge MA, US

International Classification:

G06F 17/30

US Classification:

707005000

Abstract:

A content-based method of managing a collection of documents is disclosed. A user interface is provided for managing the collection of documents. For each document, at least one information object representative of conceptual content of a portion of the document is identified. The information objects are combined with additional conceptual information inferred from the user interface to determine a network of conceptual relationships associated with the collection of documents. The user interface provides user access to the network of conceptual relationships to manage the collection of documents.

US Patent:

20080085914, Apr 10, 2008

Filed:

Oct 6, 2005

Appl. No.:

11/576495

Inventors:

David Louis Feldman - Teaneck NJ, US
Friedrich Cameron Luft - Panketal, DE
Dominik Nicolas Mueller - Berlin, DE
Randy Lee Webb - Flemington NJ, US

International Classification:

A61K 31/40
A61K 31/33
A61K 31/41
A61K 31/44
A61K 31/445
A61P 9/00

US Classification:

514303, 514183, 514319, 514359, 514423

Abstract:

The present invention provides methods for the prevention of, delay progression to overt to, or the treatment of diastolic dysfunction or diastolic heart failure which method comprises administering to a warm-blooded animal a therapeutically effective amount of a renin inhibitor, or a pharmaceutically acceptable salt thereof, alone or in combination with

US Patent:

20080161321, Jul 3, 2008

Filed:

Mar 16, 2005

Appl. No.:

10/592973

Inventors:

David Louis Feldman - Teaneck NJ, US
Steven Zelenkofske - Center Valley PA, US
Michaela Dinboeck - Basel, CH
Margaret Forney Prescott - Morris Plains NJ, US

International Classification:

A61K 31/496
A61K 31/165
A61P 3/10
A61P 9/12
A61P 9/00
A61P 3/00

US Classification:

51425218, 514616

Abstract:

The present is directed to a method for the prevention of, delay progression to or treatment of a condition or disease selected from diabetes type 2 (associated with or without hypertension), severe hypertension, PH, malignant hypertension, isolated systolic hypertension, familial dyslipidemic hypertension, endothelial dysfunction (with or without hypertension), survival post-MI, increase of formation of collagen and other extracellular matrix proteins, restenosis after stenting, PVD including PAD and peripheral venous disorders, CAD, morbidity, mortality, cerebrovascular diseases, metabolic disorder (Syndrome X), AF, renoprotection, reduction of proteinuria, renal failure, glomerulonephritis, nephrotic syndrome, renal fibrosis, AIN, ATN, acute tubulo-interstitial nephritis, PKD, vascular inflammation, rennin secreting tumors, vasculitides or closure, restenosis of dialysis access grafts comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof alone or in combination with another active ingredient.